Robotic Athermal Nerve-Sparing Radical Prostatectomy

Stage I Prostate Cancer Clinical Trial

Official title:

Prospective Single-Center Randomized Study of Robotic Athermal Nerve-Sparing Radical Prostatectomy: Laparoendoscopic Single-Site Versus Standard Approach

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02079155
• Other study ID #: CASE12811
• Secondary ID: NCI-2014-00393CA
• Status: Withdrawn
• Phase: N/A
• First received: March 3, 2014
• Last updated: January 20, 2016
• Start date: June 2012
• Est. completion date: January 2016

Study information

• Verified date: January 2016
• Source: Case Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This randomized clinical trial compares a recently developed technique, called robotic laparoendoscopic single-site radical prostatectomy (R-LESS RP), to the current standard of robotic technique for prostate cancer, robot-assisted laparoscopic prostatectomy (RALP) in treating patients with newly diagnosed, locally confined prostate cancer. Both procedures are types of robotic radical prostatectomy, or the robot-assisted removal of the prostate though a small incision in the belly. In the standard approach, 4-5 small (1-2 cm) incisions are made in the lower abdomen to allow the insertion of robotic instruments. In the R-LESS technique, all instruments are inserted through a single incision. R-LESS RP is less invasive than RALP and may leave a smaller scar and cause less pain.

Description:

PRIMARY OBJECTIVES:

I. To evaluate pain and analgesic requirement of R-LESS RP compared to standard RALP.

SECONDARY OBJECTIVES:

I. Time to oral intake. II. Time to resume ambulation. III. Hospital stay, counted in whole days from the day of surgery to the day of discharge.

IV. Perioperative parameters, including: operative time (defined as time elapsed from skin incision to placement of the final skin suture); estimated blood loss; additional ports; conversion to standard RALP (in R-LESS RP patients), or laparoscopic, or open surgery; length of stay.

V. Intraoperative complications. VI. Postoperative complications, recorded according to the Clavien classification.

VII. Body image perception, measured using the body image questionnaire (BIQ). VIII. Scar evaluation (at suture removal and at 6 month) by using a validated assessment tool, the Patient and Observer Scar Assessment Scale.

IX. Health related quality of life, measured as patients' perception of functioning, disability, and well-being related to the following eight concepts: physical functioning, role limitations caused by physical health problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health.

X. Urinary continence, assessing the number of pads used daily. XI. Erectile Function, assessed by the International Index of Erectile Function (IIEF-5).

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients undergo standard RALP.

ARM II: Patients undergo R-LESS RP.

After completion of study treatment, patients are followed up periodically for 1 year.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2016
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 35 Years to 72 Years

Eligibility

Inclusion Criteria:

• Patients must have a biopsy proven newly diagnosed locally confined, stage T1a, T2a or T2b prostate cancer

• Judged by the study doctor to be a suitable candidate for a radical prostatectomy

• Serum prostate specific antigen equal to or less than 10 ng/mL

• Gleason score equal to or less than 7

• Life expectancy greater than 10 years

• Prostate size on trans-rectal ultrasound (TRUS) measurement less than 50 grams

• Favorable operative risk defined as American Society of Anesthesiology Score (ASA score) =< 3

• Ability to understand and the willingness to sign a written informed consent document or have a surrogate with the ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

• Patients with any prior pelvic surgery

• Patients with prior history of pelvic fractures or hip replacement

• Large pelvic or intra-abdominal masses

• Any condition or history of illness or surgery that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient (e.g. significant cardiovascular conditions)

• Poor surgical risk (defined as American Society of Anesthesiology Score > 3)

• Active infection

• Uncorrected coagulopathy

• Body mass index equal to or greater than 35

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Prostatic Neoplasms
• Stage I Prostate Cancer
• Stage IIA Prostate Cancer

Intervention

Procedure:
• robot-assisted laparoscopic surgery
Undergo RALP
• robot-assisted laparoscopic surgery
Undergo R-LESS RP

Other:
• laboratory biomarker analysis
Correlative studies
• quality-of-life assessment
Ancillary studies
• questionnaire administration
Ancillary studies

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Case Comprehensive Cancer Center	National Cancer Institute (NCI)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean pain score, evaluated with the visual analog pain score (VAPS)	Compared using the Mann-Whitney U test as appropriate.	Up to 1 year	No
Primary	Mean analgesic consumption, obtained from medical charts and reported as units of parenteral morphine equivalents (mg)	Compared using the Mann-Whitney U test as appropriate.	Up to 1 month	No
Secondary	Time to oral intake	Compared using the Mann-Whitney U test as appropriate.	Up to 1 year	No
Secondary	Time to resume ambulation	Compared using the Mann-Whitney U test as appropriate.	Up to 1 year	No
Secondary	Length of hospital stay, counted in whole days from the day of surgery to the day of discharge	Compared using the Mann-Whitney U test as appropriate.	Up to 3 days	No
Secondary	Operative time, defined as time elapsed from skin incision to placement of the final skin suture	Compared using the Mann-Whitney U test as appropriate.	Day 1	No
Secondary	Estimated blood loss during surgery	Compared using the Mann-Whitney U test as appropriate.	Day 1	No
Secondary	Additional ports during surgery	Compared using the Mann-Whitney U test as appropriate.	Day 1	No
Secondary	Incidence of conversion to standard RALP, laparoscopic, or open surgery in R-LESS RP patients	Compared by means of Fisher's exact test.	Day 1	No
Secondary	Incidence of intraoperative complications	Compared using the Mann-Whitney U test as appropriate.	Day 1	No
Secondary	Incidence of postoperative complications, recorded according to the Clavien classification	Compared using the Mann-Whitney U test as appropriate.	Up to 1 year	No
Secondary	Body image perception, measured using the BIQ	Compared using the Mann-Whitney U test as appropriate. The BIQ consists of two scales: the body image scale, which assesses attitudes to bodily appearance and consists of five questions (score 5-20), and the cosmetic scale which assesses degree of satisfaction with the appearance of the scare and consists of three questions (score 3-24).	Up to 1 year	No
Secondary	Scar evaluation, assessed using the Patient and Observer Scar Assessment Scale	Compared using the Mann-Whitney U test as appropriate. Assessed at suture removal and at 6 months. The Patient and Observer Scar Assessment Scale consists of two scales: the observer scale and the patient scale. Both scales contain 6 items that are scored numerically. Each of the six items on both scales has a 10-step score, with 10 indicating the worst imaginable scar or sensation. The total score of both scales consists of adding the scores of each of the six items (range, 6 to 60). The lowest score, 6, reflects normal skin, whereas the highest score, 60, reflects the worst imaginable scar.	Up to 1 year	No
Secondary	Health related quality of life, measured as patients' perception of functioning, disability, and well-being	Compared using the Mann-Whitney U test as appropriate. Patients' perception of functioning, disability, and well-being will be measured related to the following eight concepts: physical functioning, role limitations cause by physical health problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health.	Up to 1 year	No
Secondary	Urinary continence, assessed by the number of pads used daily	Compared using the Mann-Whitney U test as appropriate. Evaluated at 1, 3, 6, and 12 months after the procedure.	Up to 12 months	No
Secondary	Erectile function, assessed by the IIEF-5	Compared using the Mann-Whitney U test as appropriate. Evaluated once in preoperative period and at 1, 3, 6, and 12 months after the procedure.	Up to 12 months	No